MRT-6160
Small molecule
Also known as DDY391
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07737743 NCT07737743 · Sjögren's Disease Registry: NCT07737743 | 2 | Part A and B: Change from baseline in ESSDAI score (Baseline, Week 24); Part C: Change from baseline in ESSPRI (Baseline, Week 24) 2029-02-19 | In progress: results expected 19 Feb 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Sjögren's Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| MRT-6160: this drug | Phase 2 | Small molecule | VAV1 | not yet graded | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | Partial signal | NCT05673993: Primary endpoint, ESSDAI change at week 24 vs placebo: met; the release gives no figures (RemeGen, 2025-08-13). | |
| VAY736 | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Imeroprubart | Phase 2 | Monoclonal antibody | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1 | Antibody–drug conjugate | CD19 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow MRT-6160 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.